10x Genomics Inc - Ordinary Shares - Class A
TXG
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.12B
Close$
$15.09
74.1% downside
Current Fair Value
74.1% downsideOvervalued by 74.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.12 Billion |
|---|---|
| Enterprise Value | $6.72 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.35 |
| Beta | 2.04 |
| Outstanding Shares | 129,984,169 |
Return
| Return on Equity | -9.10% |
|---|---|
| Return on Assets | -7.29% |
| Return on Invested Capital | -9.60% |
Valuation & Multiples
| P/E Ratio | -95.07 |
|---|---|
| PEG | 62.58 |
| Price to Sales | 14.54 |
| Price to Book Ratio | 9.69 |
| Enterprise Value to Revenue | 10.89 |
| Enterprise Value to EBIT | -76.83 |
| Enterprise Value to Net Income | -90 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$146.67 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.26
Average shareholder expectationRevenue Estimate
$147.21 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5076▲ 44.46% |
|---|---|
| Total Calls | 13,200▼ 98.74% |
| Total Puts | 6,700▼ 89.80% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 17.95%▼ 80.57% |
|---|---|
| Total Invested | $883.65M▼ 66.73% |
| Investors Holding | 160▼ 179.00% |
ESG Score
No data
About 10x Genomics Inc
CEO: Serge Saxonov